However, according to Protein Atlas, the protein levels of ALKBH5 do not show substantial differences between normal brain tissues and GBM samples (https://www.proteinatlas.org/ENSG00000091542-ALKBH5/pathology/glioma), suggesting that post-translational modifications, such as ubiquitination, may influence the cellular levels of ALKBH5 protein. This evidence concerns the gene ALKBH5 and central nervous system cancer.